Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 29 Mar 2022
FDA authorises second booster dose of two COVID-19 vaccines for older and immunocompromised individuals
29 March 2022 - Today, the U.S. FDA authorised a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 ...
Posted by Michael Wonder on 29 Mar 2022
Nurix Therapeutics awarded Innovation Passport for entry into Innovative Licensing and Access Pathway in the United Kingdom for NX-1607
29 March 2022 - NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumour types. ...
Posted by Michael Wonder on 29 Mar 2022
European Medicines Agency validates Bristol Myers Squibb’s application for Opdivo (nivolumab) with chemotherapy as neo-adjuvant treatment for resectable non-small-cell lung cancer
29 March 2022 - Application based on CheckMate-816, the only Phase 3 trial to demonstrate improved event-free survival and pathologic complete ...
Posted by Michael Wonder on 29 Mar 2022
Gadopiclenol marketing authorisation dossier submissions accepted for review by EMA and FDA
29 March 2022 - Priority review granted by U.S. FDA. ...
Posted by Michael Wonder on 29 Mar 2022
Federal budget 2022: more funding for breast cancer drug Trodelvy
29 March 2022 - Against all the odds Sydney mum Alison Day will get to celebrate her daughter’s 12th birthday — ...
Posted by Michael Wonder on 29 Mar 2022
Lipocine announces its partner received FDA approval of Tlando
29 March 2022 - Commercial launch expected in 2Q 2022. ...
Posted by Michael Wonder on 29 Mar 2022
Government fails to adequately address medicine affordability for working Australians
29 March 2022 - The cost of medicines will continue to go up unchecked as the Federal Government has failed ...
Posted by Michael Wonder on 29 Mar 2022
Novo Nordisk receives FDA approval of higher-dose Ozempic 2 mg providing increased glycemic control for adults with type 2 diabetes
28 March 2022 - Ozempic demonstrated 2.1% blood sugar reduction and also weight loss in adults with type 2 diabetes ...
Posted by Michael Wonder on 29 Mar 2022
Santhera and ReveraGen start rolling NDA submission to the FDA for vamorolone for the treatment of Duchenne muscular dystrophy
29 March 2022 - Santhera Pharmaceuticals and ReveraGen BioPharma announce the initiation of a rolling new drug application submission to the ...
Posted by Michael Wonder on 29 Mar 2022
Consequences of US FDA approval decisions in high-income countries
29 March 2022 - Akhade and colleagues highlight the global consequences of approving cancer medicines on the basis of uncertain evidence ...
Posted by Michael Wonder on 29 Mar 2022
Tarlige tablets approved in Japan for treatment of patients with neuropathic pain
28 March 2022 - Daiichi Sankyo today announced that it has obtained approval in Japan to change the indication of ...
Posted by Michael Wonder on 29 Mar 2022
Budget 2022-23 – no ‘big bang’ announcements in health
29 March 2022 - Medicines Australia welcomes tonight’s Budget announcements for new PBS listings and on-going COVID-19 measures. ...
Posted by Michael Wonder on 29 Mar 2022
Record investment in the future of Australia's health system
29 March 2022 - The Australian Government is investing in a stronger health system as part of our plan for a ...
Posted by Michael Wonder on 29 Mar 2022
Neurocrine Biosciences announces regulatory approval of Dysval (valbenazine) for the treatment of tardive dyskinesia in Japan
29 March 2022 - Neurocrine Biosciences today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation, has obtained regulatory approval of ...
Posted by Michael Wonder on 29 Mar 2022
Ondexxya approved in Japan for reversal of acute major bleeds in patients on factor Xa inhibitors
29 March 2022 - Ondexxya is the first approved reversal agent specifically for factor Xa inhibitors, providing a major advance ...